Clinical evaluation of new patient dedicated blood gas analyser published


Results from evaluation study of Proxima miniature inline analyser demonstrate excellent agreement with benchtop blood gas analyser

Sphere Medical has announced the results of a clinical study evaluating its new Proxima miniature inline blood gas analyser.

The study included 20 intensive care unit patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery and sepsis. Patients were monitored using the Proxima patient dedicated analyser for up to three days. Each time a sample was tested on the patient dedicated analyser, a concurrent sample was drawn and tested on the hospital’s benchtop analyser (Roche Diagnostics’ Cobas b221). Results demonstrated excellent agreement for pH, pCO2, pO2 and K+ between the analysers, while Proxima could be used for trend analysis for Haematocrit.

The study also observed the potential of patient-dedicated arterial blood gas analysers to allow close monitoring of critically-ill patients without leaving the patient’s bedside or net loss of blood for the patient.

The study concluded that: “Proxima is well suited to enable staff to more closely manage unstable and critically-ill patients. This device may be of significant benefit to patients at risk of iatrogenic anaemia or those being treated in side and isolation rooms.

Blood gas is considered a ‘vital sign’ that requires monitoring to ensure the effective management of patients in the critical care environment, particularly for those that are unstable.

Sign up for your free email newsletter

Maintenance of tissue oxygenation, ventilation and acid-base status is a major concern for most ICUs, since life-threatening changes in these characteristics can occur suddenly and so rapid results are often needed for effective patient monitoring and treatment.